Karen Akinsanya serves as the President of R&D, Therapeutics at Schrödinger Inc., a leading company in the field of computational chemistry and materials science. With an impressive background in pharmaceutical research and development, Dr. Akinsanya brings a wealth of experience and expertise to her role. She holds a Ph.D. in Pharmacology from the University of Pennsylvania and has spent over two decades in the industry, working with major pharmaceutical companies such as Merck and Bristol-Myers Squibb. Throughout her career, Dr. Akinsanya has been instrumental in advancing drug discovery and development programs, particularly in the areas of oncology and immunology. Her leadership and strategic vision have been key to the success of numerous projects, resulting in several promising drug candidates entering clinical trials. At Schrödinger, she oversees the company's efforts to leverage its cutting-edge computational platform to design novel therapeutics, collaborating closely with internal teams and external partners to accelerate the drug discovery process. In her current role as President of R&D, Therapeutics, Dr. Akinsanya is responsible for guiding the company's therapeutic research strategy and ensuring the successful translation of Schrödinger's computational insights into tangible medical solutions. Her dedication to improving patient outcomes and her ability to foster a culture of innovation have made her an invaluable asset to the company. Under her leadership, Schrödinger continues to push the boundaries of what is possible in drug discovery, with the ultimate goal of bringing life-changing treatments to patients worldwide.